Some images has been designed using resources from Unsplash & Pixabay & Pexels & Freepik and some icons from Flaticon
跳到主要內容
:::
:::

蕭樑材主任

蕭樑材主任

學歷

國立陽明交通大學臨床醫學研究所博士

國立陽明交通大學醫學系 醫學士

現職

臺北榮民總醫院內科部血液科主治醫師

臺北榮民總醫院血液科主任

國立陽明交通大學醫學系內科學科部定副教授

中華民國血液病學會甄審委員

中華民國血液及骨髓移植學會理事

臺灣癌症臨床研究發展基金會醫療顧問

經歷

 - 公職醫師高等考試優等

 -灣橋榮民醫院內科住院醫師

 -臺北榮民總醫院內科部住院醫師

 -臺北榮民總醫院內科部腫瘤科住院總醫師

 -中華民國血液病學會秘書長

 -中華民國血液及骨髓移植學會甄審委員

醫療專長

淋巴瘤、白血病、多發性骨髓瘤、血液及骨髓幹細胞移植、貧血及血小板、腫瘤內科學

證照

中華民國內科醫學會內科專科醫師、中華民國血液病學會血液病專科醫師、中華民國癌症醫學會腫瘤內科專科醫師、中華民國血液及骨髓移植專科醫師、中華民國癌症安寧緩和醫學專科醫師

語言專長

國語 、台語英語

代表著作

 

  1. Wang HY, Yang CF, Chiou TJ, Yang SH, Gau JP, Yu YB, Chen PM, Hsu HC, Fung CP, Lin HY, Tzeng CH, Liu JH, Hsiao LT*. Risk of hemophagocytic lymphohistiocytosis in adults with fevers of unknown origin: the clinical utility of a new scoring system on early detection. Hematol Oncol. 2016 June 24 (in press). (*correspondence)
  2. Hsiao LT, Wang HY, Yang CF, Chiou TJ, Gau JP, Yu YB, Liu HL, Chang WC, Chen PM, Tzeng CH, Chan YJ, Yang MH, Liu JH, Huang YH. Human Cytokine Genetic Variants Associated With HBsAg Reverse Seroconversion in Rituximab-Treated Non-Hodgkin Lymphoma Patients. Medicine (Baltimore) 2016; 95:e3064.
  3. Yang SH, Hsiao LT*, Chiou TJ, Yang CF, Yu YB, Liu CY, Gau JP, Liu JH, Chen PM, Tzeng CH. Rituximab induction therapy, survival benefits, and the increasing selection of radiotherapy as the postinduction treatment in patients with primary mediastinal large B-cell lymphoma. J Chin Med Assoc 2015; 78:400-407.
  4. Hsiao LT, Chiou TJ, Gau JP, Yang CF, Yu YB, Liu CY, Liu JH, Chen PM, Tzeng CH, Chan YJ, Yang MH, Huang YH. Risk of Reverse Seroconversion of Hepatitis B Virus Surface Antigen in Rituximab-Treated Non-Hodgkin Lymphoma Patients: A Large Cohort Retrospective Study. Medicine (Baltimore). 2015;94(32):e1321.
  5. Hsiao LT, Tien HF, Kuo CY, Wu JH, Hou HA, Wang MC, Liu CY, Chen PM, Chiou TJ. Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Hematol Oncol. 2015;33(4):136-44
  6. Wang HY, Yang CF, Chiou TJ, Yang SH, Gau JP, Yu YB, Liu CY, Liu JH, Chen PM, Hsu HC, Fung CP, Tzeng CH, Hsiao LT*. A "bone marrow score" for predicting hematological disease in immunocompetent patients with fevers of unknown origin. Medicine (Baltimore). 2014;93(27):e243.
  7. Hsiao LT*, Chung FP, Chiou TJ, Chen PM, Tzeng CH. The limitations of extracorporeal membrane oxygenation as a bridge to allogeneic hematopoietic stem cell transplantation. Intensive Care Med. 2014;40(12):1971-2.
  8. Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, Liu CY, Yang MH, Tzeng CH, Lee PC, Lin HC, Lee SD. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31:2765-2772.
  9. Yang SH, Teng HW, Hong YC, Liu CY, Yu YB, Yang CF, Gau JP, Liu JH, Chang TJ, Yen JJ, Chen PM, Chiou TJ, Tzeng CH, Hsiao LT*. International Staging System predicts prognosis of Chinese patients with multiple myeloma across different calendar periods with application of novel agents. Ann Hematol 2012; 91:93-102.
  10. Hsiao LT*, Yang CF, Yang SH, Gau JP, Yu YB, Hong YC, Liu CY, Liu JH, Chen PM, Chiou TJ, Tzeng CH. Chronic kidney disease stage 5 as the prognostic complement of International Staging System for multiple myeloma. Eur J Haematol 2012; 88:159-166.
  11. Chou YS, Yang CF, Chen HS, Yang SH, Yu YB, Hong YC, Liu CY, Gau JP, Liu JH, Chen PM, Chiou TJ, Tzeng CH, Hsiao LT*. Pre-existing diabetes mellitus in patients with multiple myeloma. Eur J Haematol 2012; 89:320-327.
  12. Hu YH, Hsiao LT*, Yang CF, Chiou TJ, Liu JH, Gau JP, Yen CC, Chou TY, Hsu WH, Chen PM, Tzeng CH. Prognostic factors of Chinese patients with primary pulmonary non-Hodgkin's lymphoma: the single-institute experience in Taiwan. Ann Hematol. 2009;88(9):839-46.
  13. Chen MH, Hsiao LT*, Chiou TJ, Liu JH, Gau JP, Teng HW, Wang WS, Chao TC, Yen CC, Chen PM. High prevalence of occult hepatitis B virus infectionin patients with B cell non Hodgkin lymphoma, Ann Hematol. 2008; 87(6): 475-80.
  14. Hsiao LT, Chiou TJ, Liu JH, Chu CJ, Lin YC, Chao TC, Wang WS, Yen CC, Yang MH, Tzeng CH, Chen PM. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2006;12(1):84-94.
  15. Hsiao LT, Lin JT, Yu IT, Chiou TJ, Liu JH, Yen CC, Wang WS, Chen PM. High serum hepatocyte growth factor level in patients with non Hodgkin lymphoma. Eur J Haematol. 2003;70(5):282-9.

 

最後更新:

回到最上